GE Healthcare licenses STEMCELL Technologies' T-Cell reagents

UK-based GE Healthcare has reached an agreement with Vancouver's STEMCELL Technologies Inc. to license the company's T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of STEMCELL Technologies' T-Cell reagents for the isolation, activation, and culture of T-cells in clinical applications, which are critical tools in the development and manufacturing of cell and gene therapies intended for administration to patients. GE has made other significant investments in the rapidly growing cell therapy and regenerative medicine industry this year, including a US $31.5 million co-investment with the Canadian government to create BridGE@CCRM for the acceleration of cellular technologies.

Click here to read the full article.